CPT® Code 81218

The CPT® Code 81218 pertains to the molecular genetic testing of the CEBPA gene, which is crucial for understanding certain types of acute myeloid leukemia (AML). This test involves a comprehensive analysis of the full gene sequence of CEBPA, which is located on the q arm of chromosome 19 at position 13.1. The primary purpose of this genetic analysis is to identify mutations within the CEBPA gene, including substitutions, insertions, and deletions. These mutations can significantly impact the diagnosis and prognosis of acute myeloid leukemia, as they help in assigning a specific sub-classification of the disease. The CEBPA gene encodes for the CCAAT/enhancer binding protein alpha, a transcription factor that plays a vital role in regulating gene expression by binding to specific DNA regions. This protein is essential for the maturation and differentiation of blood cells and acts as a tumor suppressor, controlling the growth and division of these cells. In cases of familial acute myeloid leukemia, certain inherited mutations in the CEBPA gene can disrupt normal blood cell production, leading to the disease. Notably, only one mutated copy of the gene is sufficient to cause familial AML, although it often coexists with additional somatic mutations in leukemic cells. Both inherited and sporadic forms of AML associated with CEBPA mutations can result in cytogenetically normal acute myeloid leukemia (CN-AML). The identified mutations typically lead to the production of an abnormally short protein that compromises the tumor suppressor functions of the normal CCAAT/enhancer binding protein alpha, thereby impairing its ability to regulate gene expression and resulting in the overproduction of abnormal white blood cells. The testing process involves obtaining blood and/or bone marrow samples, which are then analyzed for gene mutations using advanced techniques such as polymerase chain reaction (PCR) combined with massively parallel sequencing and genomic microarray methodologies.